Zipalertinib (CLN-081)

Name: Zipalertinib (CLN-081) in EGFR exon 20 insertion-mutated non-small-cell lung cancer: Prevalence of EGFR exon 20 insertion-mutated non-small-cell lung cancer
Published: 2026-09-14T15:39:06-04:00

EGFR exon 20 insertion-mutated non-small-cell lung cancer

Also known as TAS6417

Manufacturer: Taiho Oncology
Regulatory submission: NDA submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Epidemiology

Prevalence of EGFR exon 20 insertion-mutated non-small-cell lung cancer

1 evidence topic · 2 sources

Frequency in a genomic-profiling series

“Of 14,483 NSCLC cases, CGP identified 263 (1.8%) cases with EGFRex20ins, representing 12% (263/2,251) of cases with EGFR mutations.” (opens the source at this quote in a new tab)

U.S. population prevalence per 100,000 for the anticipated indication

No evidence found.